# Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers

> **NCT02454699** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 24 (actual)

## Conditions studied

- Cytomegalovirus Infection

## Interventions

- **DRUG:** MBX400
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02454699
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-10
- **Primary completion:** 2017-04-01
- **Final completion:** 2017-12-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02454699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02454699, "Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT02454699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*